Business
Related party loan to ProAxsis Limited
Related party loan to ProAxsis Limited.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n For release: 07.00, 28 February 2023\n \n \n \n \n NetScientific plc\n \n \n \n (\"NetScientific\" or \"NSCI\" or the \"Company\" or the \"Group\")\n \n \n \n Related party loan to ProAxsis Limited (\"ProAxsis\")\n \n \n \n \n London, UK - 28 February 2023:\n \n NetScientific plc (AIM: NSCI), the investment and commercialisation group with an international portfolio of innovative life science, sustainability, and technology companies, announces that, on 27 February 2023, its wholly owned portfolio company, respiratory diagnostics specialist, ProAxsis, entered into an unsecured £500,000 six month loan agreement (the \"Loan Agreement\") with AB Group Limited (\"AB Group\").\n \n \n The rate of interest applicable to the loan is 10 per cent. per annum, payable on repayment of the loan. In addition, ProAxsis has granted to AB Group warrants over shares in ProAxsis equal to the value of £150,000 at an exercise price determined by reference to a future third party fundraising of at least £500,000, such price to be discounted by 30 per cent. The warrants have an exercise period commencing on the date of any such third party fundraising and ending on the five year anniversary of the date of the Loan Agreement.\n \n \n As AB Group, together with other entities associated with Melvin Lawson, is interested in 16.88 per cent. of the issued share capital of NetScientific, its entry into the Loan Agreement represents a related party transaction under Rule 13 of the AIM Rules for Companies.\n \n \n The Directors of the Company, each of whom is independent of AB Group, consider, having consulted the Company's Nominated Adviser, that the terms of the Loan Agreement are fair and reasonable insofar as the Company's shareholders are concerned. In reaching this conclusion, the Directors have taken into account the limited availability of loan finance to ProAxsis from alternative sources.\n \n \n \n Commenting on the Loan Agreement, Dr Ilian Iliev, Chief Executive Officer of NetScientific said\n \n :\n \n \n \n \"A key element of our capital light investment approach is to help our portfolio companies access funding from third parties. We are therefore delighted to have helped secure this Loan Agreement for ProAxsis, which will help it accelerate its commercial and investment strategy in the respiratory diagnostics space. \n \n...